Cresemba under the microscope: Real-World safety check for fungal infections
NCT ID NCT04744454
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how safe and effective the drug Cresemba (isavuconazole) is for Korean patients with serious fungal infections like invasive aspergillosis or mucormycosis. Researchers tracked side effects and how well the drug worked in 94 adults. The goal was to confirm the drug's safety and effectiveness in real-world use, as required by Korean health authorities.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Isavuconazole (brand name Cresemba)
What this could lead to
If results are positive, it could confirm that Cresemba is a safe and effective option for treating serious fungal infections in Korean patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also small (94 people) and only in Korea, so findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCORMYCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Korea
Seoul, South Korea